The in vitro spliceosome assembly pathway is conserved between yeast and mammals as U1 and U2 snRNPs associate with the pre-mRNA prior to U5 and U4/U6 snRNPs. In yeast, U1 snRNP-pre-mRNA complexes are the first splicing complexes visualized on native gels, and association with U1 snRNP apparently commits pre-mRNA to the spliceosome assembly pathway. The current study addresses U2 snRNP addition to commitment complexes. We show that commitment complex formation is relatively slow and does not require ATP, whereas U2 snRNP adds to the U1 snRNP complexes in a reaction that is relatively fast and requires ATP or hydrolyzable ATP analogs. In vitro spliceosome assembly was assayed in extracts derived from strains containing several U1 sRNA mutations. The results were consistent with a critical role for U1 snRNP in early complex formation. A mutation that disrupts the base-pairing between the 5' end of U1 snRNA and the 5' splice site allows some U2 snRNP addition to bypass the ATP requirement, suggesting that ATP may be used to destabilize certain U1 snRNP:pre-mRNA interactions to allow subsequent U2 snRNP addition.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC334131 | PMC |
| http://dx.doi.org/10.1093/nar/20.16.4237 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cancer-associated SF3B1 mutation K700E causes widespread changes in U2/branchpoint recognition without altering splicing.
bioRxiv
November 2024
Department of Microbiology, Immunology, and Molecular Genetics, Molecular Biology Institute, David Geffen School of Medicine, UCLA, Los Angeles, CA.
Myelodysplastic syndromes and other cancers are often associated with mutations in the U2 snRNP protein SF3B1. Common SF3B1 mutations, including K700E, disrupt SF3B1 interaction with the protein SUGP1 and induce aberrant activation of cryptic 3' splice sites (ss), presumably resulting from aberrant U2/branch site (BS) recognition by the mutant spliceosome. Here, we apply the new method of U2 IP-seq to profile BS binding across the transcriptome of K562 leukemia cells carrying the K700E mutation.
View Article and Find Full Text PDFExpanding the landscape of systemic sclerosis-related autoantibodies through RNA immunoprecipitation coupled with massive parallel sequencing.
J Autoimmun
December 2024
Systemic Autoimmune Diseases Unit, Internal Medicine Department, Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Systemic Autoimmune Diseases Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Article Synopsis
- The study focused on creating a new test to detect specific autoantibodies in patients with systemic sclerosis (SSc) using RNA immunoprecipitation and massive parallel sequencing techniques.
- Researchers analyzed serum samples from 307 SSc patients, with 57 undergoing detailed testing that identified 30,966 RNA molecules, ultimately narrowing down to 197 significant molecules linked to SSc-related autoantibodies.
- The new assay demonstrated high sensitivity and specificity in detecting autoantibodies, revealing not only known targets but also potential new ones associated with different clinical aspects of SSc.
Commitment Complex Splicing Factors in Cancers of the Gastrointestinal Tract-An In Silico Study.
Bioinform Biol Insights
October 2024
Department of Biomedical Sciences, Mercer University School of Medicine, Macon, GA, USA.
The initial step in pre-mRNA splicing involves formation of a spliceosome commitment complex (CC) or E-complex by factors that serve to bind and mark the exon-intron boundaries that will undergo splicing. The CC component U1 snRNP assembles at the 5'-splice site (ss), whereas SF1, U2AF2, and U2AF1 define the 3'-ss of the intron. A PRP40 protein bridges U1 snRNP with factors at the 3'-ss.
View Article and Find Full Text PDFSNRPB2 in the pan-cancer landscape: A bioinformatics exploration and validation in hepatocellular carcinoma.
Cell Signal
December 2024
Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330000, Jiangxi Province, China. Electronic address:
Article Synopsis
- * Analysis of public cancer data highlighted increased SNRPB2 expression across various cancers, often correlating with poor patient outcomes and connections to cancer-related processes.
- * Experimental studies showed that reducing SNRPB2 levels decreased liver cancer cell growth and movement, suggesting its potential as a biomarker and target for immunotherapy in cancer treatment.
Dual diagnosis of achondroplasia and mandibulofacial dysostosis with microcephaly.
BMC Med Genomics
September 2024
Faculty of Health and Life Sciences, University of Liverpool, Liverpool, L69 7ZB, UK.
Article Synopsis
- The case study discusses a female patient diagnosed with achondroplasia due to an FGFR3 gene variant, but her symptoms indicated a more complex condition, prompting further genetic analysis.* -
- Despite her initial diagnosis, the patient exhibited unusual features such as small head size, distinct facial characteristics, speech delay, and hearing loss, leading to her participation in extensive genetic research efforts.* -
- Ultimately, the discovery of an EFTUD2 gene rearrangement revealed a second diagnosis of mandibulofacial dysostosis with microcephaly, marking a rare instance of dual genetic disorders in one individual and emphasizing the need for careful genetic evaluations.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!